Viewing Study NCT00408967

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:27 AM
Ignite Modification Date: 2026-01-28 @ 3:29 PM
Study NCT ID: NCT00408967
Status: WITHDRAWN
Last Update Posted: 2017-08-18
First Post: 2006-12-06
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.
Sponsor: EMD Serono
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Ovarian Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Ovarian View
None Cancer View
None Epithelial View
None Recurrent View
None Platinum View
None Second-line therapy View
None Maintenance Therapy View
None Biologic View
None Targeted Therapy View
None Antibody View